Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
16.48
-0.14 (-0.84%)
At close: Jun 8, 2026, 4:00 PM EDT
16.45
-0.03 (-0.18%)
After-hours: Jun 8, 2026, 7:41 PM EDT
Zai Lab Revenue
Zai Lab had revenue of $99.61M in the quarter ending March 31, 2026, a decrease of -6.46%. This brings the company's revenue in the last twelve months to $453.28M, up 8.36% year-over-year. In the year 2025, Zai Lab had annual revenue of $460.16M with 15.33% growth.
Revenue (ttm)
$453.28M
Revenue Growth
+8.36%
P/S Ratio
4.08
Revenue / Employee
$254,081
Employees
1,784
Market Cap
1.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 460.16M | 61.17M | 15.33% |
| Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
| Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
| Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
| Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
| Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
| Dec 31, 2019 | 12.99M | 12.86M | 9,965.89% |
| Dec 31, 2018 | 129.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lakefront Biotherapeutics NV | 1.20B |
| Harmony Biosciences Holdings | 899.11M |
| ADMA Biologics | 509.86M |
| Vericel | 292.09M |
| Intellia Therapeutics | 66.09M |
| Mesoblast | 65.38M |
| Nektar Therapeutics | 55.63M |
| Nanobiotix | 38.27M |
ZLAB News
- 1 hour ago - Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer - Business Wire
- 7 days ago - Zai Lab (ZLAB) Q1 2026 Earnings Transcript - The Motley Fool
- 17 days ago - Zai Lab (ZLAB) Announces Leadership Change Amid Strategic Developments - GuruFocus
- 18 days ago - Zai Lab announces departure of COO Josh Smiley - TheFly
- 18 days ago - Zai Lab Announces Changes to Senior Leadership Team - Business Wire
- 23 days ago - Insider Sell Alert: Edmondson Frazor Titus III Sells Shares of Zai Lab Ltd (ZLAB) - GuruFocus
- 4 weeks ago - Zai Lab (ZLAB) Achieves Fast Track Status for New Cancer Treatment - GuruFocus
- 4 weeks ago - Zai Lab receives FDA Fast Track Designation for zocilurtatug pelitecan - TheFly